Portfolio of Stem Cell Stocks

Here is a table of 10 stem cell stocks.

10 Stem Cell Stocks

Stock Returns & Price Chart


Recent Prices &
Annualized Return

Brainstorm Cell TherapeuticsBCLI
Caladrius BiosciencesCLBS
Cesca TherapeuticsKOOL
Pluristem TherapeuticsPSTI
Sangamo TherapeuticsSGMO
VistaGen TherapeuticsVTGN
Price data from Quandl as of most recent close.

To inspect the performance of the Stem Cell Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.

The 9 stocks included in the portfolio computations are: ATHX, BCLI, CLBS, KOOL, GERN, CUR, PSTI, SGMO and VCEL. The current value of the portfolio assumes that $1,111.11 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends. VTGN was excluded from the portfolio computations because of insufficient price data.

The current value of a $10,000 investment is $4,616. The percent return is -53.84%. The annualized return is -7.44%.

Return Summary for Stem Cell Stocks
Start DateSep-30-2009
Start Investment$10,000.00
End DateSep-19-2019
Current Value of Investment$4,615.56
Total Return-53.84%
Annualized Return-7.44%
Min DateJan-31-2017
Min Price$3,711.56
Max DateFeb-28-2014
Max Price$15,046.02
# Values121
Number Returns7,260
Number Profitable Returns1,834
Percent Profitable Returns25.26%
Number Unprofitable Returns5,426
Percent Unprofitable Returns74.74%
Profitable to Unprofitable Returns Ratio0.34

NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.

Related Portfolios

Portfolio of Gene Editing (CRISPR) Stocks

Portfolio of Genetic Testing Stocks

Portfolio of Genomics Stocks